Bristol-Myers Squibb Company (BMY) · page 148 of 197
The slide attempts to frame the Celgene merger as a 'poison pill' or entrenchment strategy rather than a strategic business decision.
Activist deck · expose_contradiction · expose_contradiction · dense density
Slide locked Sign in to view
Slide schematic 7/7
callout 1/1 diagram 1/1 list 1/1 paragraph 1/1 source-note 1/1 table 1/1 title 1/1
Components 7
primary timeline bullet paragraph source-note data headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1